Inactivation of the human brain muscarinic acetylcholine receptor by oxidative damage catalyzed by a low molecular weight endogenous inhibitor from Alzheimer's brain is prevented by pyrophosphate analogs, bioflavonoids and other antioxidants

Brain Research

Volumn 950, Issue 1-2, 2002, Pages 10-20

  Fawcett, John R ^a   Bordayo, Elizabeth Z ^a   Jackson, Kathy ^a   Liu, Howard ^a   Peterson, Jennifer ^a   Svitak, Aleta ^a   Frey Ii, William H ^a  

^a HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

Author keywords

Antioxidant; Bioflavonoid; Free radical; Heme; Hydrogen peroxide; Inhibitor; Muscarinic acetylcholine receptor; Pyrophosphate

Indexed keywords

ANTIOXIDANT; BILIRUBIN; BILIVERDIN; BIOFLAVONOID; BISPHOSPHONIC ACID DERIVATIVE; CARNOSOL; CHOLINESTERASE INHIBITOR; FREE RADICAL; GLUTATHIONE; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; MYRICETIN; OXYGEN; PEROXIDASE; PEROXIDE; PYROPHOSPHATE; PYROPHOSPHORIC ACID DERIVATIVE; QUERCETIN;

ALZHEIMER DISEASE; ARTICLE; CATALYSIS; CHOLINERGIC ACTIVITY; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN TISSUE; LIGAND BINDING; MEMORY; MOLECULAR WEIGHT; OXIDATIVE STRESS; PRIORITY JOURNAL;

ALZHEIMER DISEASE; ANTIOXIDANTS; BRAIN; CATALYSIS; DIPHOSPHATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONOIDS; HEMEPROTEINS; HUMANS; MUSCARINIC ANTAGONISTS; NERVE TISSUE PROTEINS; OXIDATIVE STRESS; RECEPTORS, MUSCARINIC;

EID: 0037144187     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)02981-5     Document Type: Article

References (46)

1. Albro P.W., Corbett J.T., Schroeder J.L. Generation of hydrogen peroxide by incidental metal ion-catalyzed autooxidation of glutatione. J. Inorg. Biochem. 27:1986;191-203.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition, Review:2000;American Psychiatric Association, Washington DC.
3. Boyer J.L., Martinez-Carcamo M., Monroy-Sanchez J.A., Posadas C., Garcia-Sainz J.A. Guanine nucleotide-induced positive cooperativity in muscarinic-cholinergic antagonist binding. Biochem. Biophys. Res. Commun. 134:1986;172-177.
4. Broody K.R., Hosain P., Spencer R.P., Hosain F., Phil D., Wagner H.N. Technetium-99m labelled imidodiphosphate: an improved bone-scanning radiophamaceutical. Br. J. Radiol. 49:1976;267-269.
5. S. Budavari, M.J. O'Neil, A. Smith, P.E. Heckelman, J.F. Kinneary (Eds.), The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals, 12th Edition, Merck and Co., Inc., Whitehouse Station, NJ, 1996, p. 205.
6. Buxbaum J.D., Oishi M., Chen H.I., Pinkas-Kramarski R., Jaffe E.A., Grandy S.E., Greengard P. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer Beta/A4 amyloid precursor protein. Proc. Natl. Acad. Sci. USA. 89:1992;10075-10078.
7. Commenges D., Scotet V., Renaud S., Jacqmin-Gadda H., Barberger-Gate P., Dartigues J.F. Intake of flavonoids and risk of dementia. Eur. J. Epidemiol. 16:2000;357-363.
8. Coyle J., Kershaw P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol. Psychiatry. 49:2001;289-299.
9. Davies P., Maloney A.J.F. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 2:1976;1403.
10. De Souza E.B. Preclinical strategies for symptomatic treatment of cognitive deficits seen in Alzheimer's Disease: Focus on cholinergic mechanisms, in Alzheimer's Disease. Corain B., et al. Advances in Clinical and Basic Research. 1993;539-548 Wiley, New York.
11. Farlow M., Anand R., Messina J. Jr., Harman R., Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur. Neurol. 44:2000;236-241.
12. Fields J.Z., Roeske W.R., Morkin E., Yamamura M.I. Cardiac muscarinic cholinergic receptors. J. Biol. Chem. 253:1978;3251-3258.7.
13. Frey II W.H., Emory C.R., Wiebenga M.E., Saxena S., Cardelli D., Ala T.A., Tollefson G.D. Inhibitor of antagonist binding to the muscarinic receptor is elevated in Alzheimer's brain. Brain Res. 655:1994;153-160.
14. Frey II W.H., Najarian M.M., Kumar K.S., Emory C.E., Menning P.M., Frank J.C., Johnson M.N., Ala T.A. Endogenous Alzheimer's brain factor and oxidized glutathione inhibit antagonist binding to the muscarinic receptor. Brain Res. 714:1996;87-94.
15. Genis I., Fisher A., Michelson D.M. Site-specific dephosphorylation of tau of apolipoprotein E-deficient and control mice by M1 muscarinic agonist treatment. J. Neurochem. 72:1999;206-213.
16. Hake A.M. Use of cholinesterase inhibitors for treatment of Alzheimer's disease. Cleve. Clin. J. Med. 68:2001;608-616.
17. 3[H]Bilirubin. Pediatric Res. 49:2001;203-207.
18. Hortobagyi G.N., Theriault R.L., Lipton A., Porter L., Blayney D., Sinoff C., Wheeler H., Simeone J.F., Seaman J.J., Knight R.D., Heffernan M., Mellars K., Reitsma D.J. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia breast cancer study group. J. Clin. Oncol. 16:1998;2038-2044.
19. Kanowski S., Herrmann W.M., Stephan K., Wierich W., Horr R. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry. 29:1996;47-56.
20. Katzman R., Thal L.J. The neurochemistry of Alzheimer's disease. Siegel G., Arganoff B., Alberts R.W., Molinoff P., Basic Neurochemistry. 1989;827-838 Raven Press, New York.
21. Khachaturian Z.S. Diagnosis of Alzheimer's Disease. Arch. Neurol. 42:1985;1097-1105.
22. Lander C.J., Lee J.M. Reduced high-affinity agonist binding at the M(1) muscarinic receptor in Alzheimer's disease brain: differential sensitivity to agonists and divalent cations. Exp. Neurol. 158:1999;451-458.
23. Marks M.J., Collins A.C. Characterization of nicotine binding in mouse brain and comparison with the binding of alpha-bungarotoxin and quinuclidinyl benzilate. Mol. Pharmacol. 22:1982;554-564.
24. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., Berg L. The consortium to establish a registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's Disease. Neurology. 41:1991;479-486.
25. Mohs R.C., Doody R.S., Morris J.C., Ieni J.R., Rogers S.L., Perdomo C.A., Pratt R.D. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 57:2001;481-488.
26. Monji A., Utsumi H., Ueda T., Imoto T., Yoshida I., Hashioka S., Tashiro K., Tashiro N. The relationship between the agregational state of the amyloid-beta peptides and free radical generation by the peptides. J. Neurochem. 77:2001;1425-1432.
27. Nitsch R.M., Wurtman R.J., Growdon J.H. Regulation of APP processing: potential for the therapeutical reduction of brain amyloid burden. Ann. N.Y. Acad. Sci. 777:1996;175-182. and 759-767.
28. A. Nunomura, G. Perry, G. Aliev, K. Hirai, A. Takeda, E.K. Balraj, P.K. Jones, H. Ghanbari, T. Wataya, S. Shimohama, S. Chiba, C. Atwood, R.B. Peterson, M.A. Smith, Oxidative damage is the earliest event in Alzheimer's disease, J. Neuropathol. Exp. Neurol. 60 (2001).
29. Ocken B.S., Storzbach D.M., Kaye J.A. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch. Neurol. 55:1998;1409-1415.
30. Pavia J., de Ceballos M.L., Sanchez de la Cuesta F. Alzheimer's disease: relationship between muscarinic cholinergic receptors, beta-amyloid and tau proteins. Fundam. Clin. Pharacol. 12:1998;473-481.
31. Premkumar D.R., Smith M.A., Richey P.L., Peterson R.B., Castellani R., Krishnan K., Wiggert B., Perry G., Kalaria R. Induction of heme oxygenase-1 mRNA and protein in neocortex and cerebral vessels in Alzheimer's disease. J. Neurochem. 65:1995;1399-1402.
32. Rhine W.D., Schmitter S.P., Yu A.C., Eng L.F., Stevenson D.K. Bilirubin toxicity and differentiation of cultured astrocytes. J. Perinatol. 19:2001;206-211.
33. Rodriguez-Puertas R., Pascual J., Vilaro T., Pazos A. Autoradiographic distribution of M1, M2, M3, and M4 muscarinic receptor subtypes in Alzheimer's Disease. Synapse. 26:1997;341-350.
34. Rottkamp C.A., Nunomura A., Raina A.K., Sayre L.M., Perry G., Smith M.A. Oxidative stress, antioxidants and Alzheimer's disease. Alzheimer Dis. Assoc. Dis. 14:2000;S62-S66.
35. Sadot E., Gurwitz D., Barg J., Behar L., Ginzburg I., Fischer A. Activation of M1 muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells. J. Neurochem. 66:1996;877-880.
36. Sadrzadeh S.M., Graf E., Panter S.S., Hallaway P.E., Eaton J.W. Hemoglobin. A biologic fenton reagent. J. Biol. Chem. 23:1984;14354-14356.
37. Schipper H.M., Cisse S., Stopa G.S. Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain. Ann. Neurol. 37:1995;758-768.
38. Smith M.A., Kutty R.K., Richey P.L., Yan S., Stern D., Chader G.J., Wiggert B., Petereson R.B., Perry G. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am. J. Pathol. 145:1994;42-47.
39. Smith M.A., Nunomura S., Zhu X., Takeda A., Perry G. Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer's disease. Anti. Redox. Signalling. 2:2000;413-420.
40. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzane M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Ann. Biochem. 150:1985;76-85.
41. Soto-Otero R., Mendez-Alvarez E., Hermida-Ameijeiras A., Sanchez-Sellero I., Cruz-Landeira A., Lamas M.L. Inhibition of brain monoamine oxidase activity by the generation of hydroxyl radicals: potential implications in relation to oxidative stress. Life Sci. 69:2001;879-889.
42. 99Tc complexes. JNM/Radiochem. Radiopharmaceutics. 16:1975;1137-1143.
43. Takahashi M., Dore S., Ferris C.D., Tomita T., Sawa A., Wolosker H., Borchelt D.R., Iwatsubo T., Kim S., Thinakaran G., Sisodia S.S., Snyder S.H. Amyloid precursor proteins inhibit heme oxygenase activity and augment neurotoxicity in Alzheimer's disease. Neuron. 28:2000;461-473.
44. Tsujimoto Y., Saitoh K., Kashima M., Shiozawa A., Kozuka M., Hashizume H., Kumura K., Yamazaki M., Fujii A. Effect of nonsteroidal anti-inflammatory drugs on lipid peroxidation by hydroxyl radical. Gen. Pharmacol. 31:1998;405-408.
45. Venters Jr H.D., Bonilla L.E., Jensen T., Garner H.P., Bordayo E.Z., Najarian M.M., Ala T.A., Mason R.P., Frey II W.H. Heme from Alzheimer's brain inhibits muscarinic receptor binding via thiyl radical generation. Brain Res. 764:1997;93-100.
46. Whitehouse P.J., Price D.L., Strubel R.G., Clark A.W., Coyle J.T., DeLong M.R. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 215:1982;1237-1239.